Bibliographic Details
| Title: |
The Potential Benefits of HPV E6/E7 mRNA Test in Cervical Cancer Screening in China |
| Authors: |
Shao-Kai Zhang, Zhen Guo, Peng Wang, Le-Ni Kang, Man-Man Jia, Ze-Ni Wu, Qiong Chen, Xiao-Qin Cao, Dong-Mei Zhao, Pei-Pei Guo, Xi-Bin Sun, Jian-Gong Zhang, You-Lin Qiao |
| Source: |
Frontiers in Oncology, Vol 10 (2020) |
| Publisher Information: |
Frontiers Media S.A., 2020. |
| Publication Year: |
2020 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
HPV – human papillomavirus, mRNA, cervical cancer, sensitiviity, specificity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
This study aims to evaluate the clinical performance of the HPV E6/E7 mRNA test in cervical cancer screening in China. A hospital-based study was conducted with mRNA, DNA, and liquid-based cytology (LBC) as primary screening tests. Each woman with a positive result received colposcopy with lesion-targeted-biopsy. Histopathological diagnosis was used as the gold standard. The total agreement of HPV DNA and mRNA was 90.7% (95%CI: 87.9, 92.9) with a kappa value of 0.81. The positive rates of HPV DNA, mRNA, and LBC increased with the severity of histopathology diagnosis, from 25.5, 19.1, and 11.4% in normal to 100.0% in SCC, respectively. The sensitivities for mRNA to detect CIN2+ and CIN3+ were 93.8% (95%CI: 89.7–96.4) and 95.7% (95%CI: 91.3–97.9), respectively, which were not different from HPV DNA testing (95.7% [95%CI: 92.0–97.7], 96.3% [95%CI: 92.1–98.3]), but higher than LBC (80.4% [95%CI: 74.5–85.2] and 88.8% [95%CI: 83.0–92.8]). The specificities for mRNA to detect CIN2+ (79.0% [95%CI: 74.2–83.0]) and CIN3+ (70.5% [95%CI: 65.7–74.9]) were higher than HPV DNA testing (71.0% [95%CI: 65.9–75.7], 62.8% [95%CI: 57.8–67.5]), but lower than LBC (84.5% [95%CI: 80.1–88.0] 79.8% [95%CI: 75.4–83.6]). All tests were more effective in women older than 30 years. HPV mRNA test showed excellent agreement with the DNA test, with similar sensitivity and a higher specificity in detecting high-grade cervical lesions. It is promising that mRNA test could be used for the national cervical cancer screening to reduce false positive without losing sensitivity. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/article/10.3389/fonc.2020.533253/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2020.533253 |
| Access URL: |
https://doaj.org/article/7b5b7b4846a4408aa9060b7ba4f3df95 |
| Accession Number: |
edsdoj.7b5b7b4846a4408aa9060b7ba4f3df95 |
| Database: |
Directory of Open Access Journals |
